Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study

SIMPLE SUMMARY: Advanced triple-negative breast cancer (TNBC) remains an extremely challenging situation in oncology, where new therapeutical strategies are desperately needed. Immunotherapy has opened a window of opportunity in this setting, with some promising results with chemo-immunotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Cruz-Merino, Luis, Gion, María, Cruz-Jurado, Josefina, Quiroga, Vanesa, Andrés, Raquel, Moreno, Fernando, Alonso-Romero, Jose L., Ramos, Manuel, Holgado, Esther, Cortés, Javier, López-Miranda, Elena, Henao-Carrasco, Fernando, Palazón-Carrión, Natalia, Rodríguez, Luz M., Ceballos, Isaac, Casas, Maribel, Benito, Sara, Chiesa, Massimo, Bezares, Susana, Caballero, Rosalia, Jiménez-Cortegana, Carlos, Sánchez-Margalet, Víctor, Rojo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582406/
https://www.ncbi.nlm.nih.gov/pubmed/34771596
http://dx.doi.org/10.3390/cancers13215432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582406/
https://www.ncbi.nlm.nih.gov/pubmed/34771596
http://dx.doi.org/10.3390/cancers13215432

Ejemplares similares